|
Match
|
Document |
Document Title |
|
|
US20120177650 |
THERAPY FOR ENTERIC INFECTIONS
A method and composition for treating enteric pathogen infections in animals suffering from such infections or displaying diseases or conditions consistent with such infections or for preventing... |
|
|
US20120148601 |
BACTERIAL SUPERANTIGEN VACCINES
The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an... |
|
|
US20150158935 |
PROTECTIVE VACCINE BASED ON STAPHYLOCOCCUS AUREUS SA2493 PROTEIN
The present invention relates to methods of inducing an immune response to Staphylococcus comprising administering a composition comprising an SA2493-related polypeptide from Staphylococcus aureus... |
|
|
US20130052204 |
(POLY)-GLYCEROLPHOSPHATE-BASED ANTI-GRAM POSITIVE BACTERIAL VACCINE
Provided are an immunogenic composition comprising polyglycerol phosphate (PGP) and methods for using the composition for treating or preventing staphylococcal infections. The PGP may be... |
|
|
US20110027265 |
Methods and Compositions Related to Immunizing Against Staphylococcal Lung Diseases and Conditions
Embodiments of the invention include methods and compositions useful in a vaccination strategy capable of neutralizing HIa to provide immunoprotection against S. aureus pneumonia. In certain... |
|
|
US20110305688 |
NEW VIRULENCE FACTORS OF STREPTOCOCCUS PNEUMONIAE
The present invention provides proteins/genes, which are essential for survival, and consequently, for virulence of Streptococcus pneumoniae in vivo, and thus are ideal vaccine candidates for a... |
|
|
US20120107327 |
IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS
The present invention relates to immunogenic compositions, comprising polypeptides and polysaccharides from Staphylococcus aureus. The present invention also relates to immunogenic compositions,... |
|
|
US20110020216 |
SCAFFOLDS FOR CELL COLLECTION OR ELIMINATION
A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that... |
|
|
US20080171054 |
TREATMENT OF MICRO-ORGANISM INFECTION
The present invention is concerned with novel antibodies, medicaments, pharmaceutical packs, methods of manufacture of medicaments and methods for the treatment of micro-organism infections,... |
|
|
US20130017203 |
METHODS OF TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS AND ASSOCIATED CONDITIONS
The present invention relates to methods and compositions for preventing and treating Staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin E... |
|
|
US20110091480 |
Antigen-Binding Proteins Targeting S. Aureus Orf0657n
The present invention features antigen binding protein that bind an ORF0657n target region (SEQ ID NO: 1). ORF0657n is an S. aureus protein. ORF0657n target regions are provided by the mAb... |
|
|
US20140017258 |
Compositions against bacterial toxins
Anti-toxin compositions are described that include avian antibodies against bacterial toxins. Administration of the anti-toxin compositions binds and neutralizes the bacterial toxin in the... |
|
|
US20140037650 |
COMPOSITIONS AND METHODS RELATED TO ANTIBODIES TO STAPHYLOCOCCAL PROTEINS ISDA OR ISDB
The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and... |
|
|
US20110033479 |
PROTEINS EZRIN, SERPIN B5, PEROXIREDOXIN-2 AND HEAT SHOCK PROTEIN BETA-1 AS AUTOANTIGENS FOR PSORIASIS VULGARIS AND POSTSTREPTOCOCCAL DISEASES
The present invention relates to autoantigens selected from Ezrin, Serpin B5, Peroxiredoxin-2, heat shock protein β1, and/or peptides comprising at least 5 consecutive amino acid residues of one... |
|
|
US20140271501 |
Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities
The present disclosure relates to methods and compositions administered to the lymphatic tissue of an animal to prevent or reduce the incidence of disease or disease symptoms caused by one or more... |
|
|
US20120027771 |
AFFINITY PURIFIED HUMAN POLYCLONAL ANTIBODIES AGAINST VIRAL, BACTERIAL AND/OR FUNGAL INFECTIONS AND METHODS OF MAKING AND USING THE SAME
The present invention discloses compositions and methods for treating, preventing and/or monitoring viral, bacterial, eukaryotic protist and/or fungal infections. In some embodiments, these... |
|
|
US20150210755 |
ANTI-POLY-N-ACETYL GLUCOSAMINE (PNAG) MONOCLONAL ANTIBODY AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF PNAG EXPRESSING BACTERIAL INFECTION
Provided are methods for the treatment or prevention of microbial infections (e.g., bacterial infection) in which the underlying pathology involves a PNAG-expressing microbe (e.g., PNAG-expressing... |
|
|
US20100233185 |
Caries Risk Test for Predicting and Assessing the Risk of Disease
Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole... |
|
|
US20080311129 |
ADHERENCE INHIBITOR DIRECTED TO AND METHOD OF MAKING AND USING
A method for the production of antibodies or microbial adherents administers is disclosed. The antibodies or microbial adherents inhibitors are administered to a patient suffering from strep... |
|
|
US20130236469 |
VACCINE AGAINST STREPTOCOCCAL INFECTIONS BASED ON RECOMBINANT PROTEINS
An antigenic composition comprises several antigenic components derived from antigens of Streptococcus equi subsp. equi or subsp. zooepidemicus, wherein at least one component is a fusion protein... |
|
|
US20120087930 |
Marker of Streptococcus Anginosus/ Streptococcus Constellatus (MOAC) and Uses Thereof
The present invention relates to nucleic acids, vectors and polypeptides that are suitable markers for detecting Streptococcus strains of the anginosus group, preferably for detecting... |
|
|
US20090074755 |
Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
The present invention relates to compositions and methods for treating Staphylococcus aureus (S. aureus) infections. In particular, the present invention provides vaccines comprising a... |
|
|
US20140271649 |
METHODS AND COMPOSITIONS FOR INHIBITING STAPHYLOCOCCUS AGGLUTINATION IN BLOOD
Certain embodiments are directed to methods of inhibiting Staphylococcal infection comprising administering effective amounts of a ClfA inhibitor and a thrombin inhibitor to a patient. |
|
|
US20100278819 |
STREPTOCOCCUS PNEUMONIAE VACCINES
Streptococcus pneumoniae is a major cause of pneumoniae, meningitis, and major cause of morbidity and mortality throughout the world by bacterial otitis media, pneumoniae, meningitis, and... |
|
|
US20140072577 |
ANTIBODIES THAT SPECIFICALLY BIND STAPHYLOCOCCUS AUREUS ALPHA TOXIN AND METHODS OF USE
Herein provided are compositions, methods of manufacture and methods of use pertaining to anti-alpha toxin antibodies and fragments. |
|
|
US20090041782 |
Novel serotype streptococcus mutans and utilization of the same
A polynucleotide encoding a polypeptide which lowers the glucose side chain amount in a serotype-specific polysaccharide antigen of Streptococcus mutans; novel Streptococcus mutans strain having... |
|
|
US20100150943 |
IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA
The invention relates to the identification of a new adhesin islands within the genomes of several Gram positive Streptococcus serotypes and isolates. Adhesin island polypeptides of the invention... |
|
|
US20070082003 |
Method for selecting and producing vaccine components and vaccines based thereon
The invention relates to the field of biology, more specifically to the field of immunology and microbiology. The invention further relates to the field of vaccines against microbial infections... |
|
|
US20100015138 |
Crystal structure of Staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof
The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the... |
|
|
US20110081347 |
Antibodies with Altered Binding to FcRn and Methods of Using Same
This invention relates to antibodies with altered binding to FcRn, and particularly antibodies having enhanced binding to FcRn and/or enhanced serum half-lives. The invention also relates to... |
|
|
US20150165015 |
USE OF ALPHA-TOXIN FOR TREATING AND PREVENTING STAPHYLOCOCCUS INFECTIONS
Vaccines comprising an S. aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections. The S. aureus alpha-toxin... |
|
|
US20110171224 |
PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION
Disclosed are pharmaceutical compositions that include a PsrP polypeptide, a nucleic acid encoding a PsrP polypeptide, or an antibody or fragment thereof that binds to a PsrP polypeptide domain,... |
|
|
US20140234338 |
THERAPEUTIC AGENT FOR USE IN A METHOD OF TREATING PSORIASIS OR ATOPIC DERMATITIS
The present invention provides a therapeutic agent for psoriasis or atopic dermatitis, and comprises anti-Staphylococcus aureus antibodies as the active ingredient. A therapeutic agent for... |
|
|
US20120322988 |
THERAPEUTIC AGENT FOR USE IN A METHOD OF TREATING PSORIASIS OR ATOPIC DERMATITIS
The present invention provides a therapeutic agent for psoriasis or atopic dermatitis, and comprises anti-Staphylococcus aureus antibodies as the active ingredient. A therapeutic agent for... |
|
|
US20060153857 |
Method of treating staphylococcus aureus infection
The present invention provides a method of preventing or treating bacteremia caused by Staphylococcus aureus, comprising administering a monoclonal or polyclonal antibody composition comprising... |
|
|
US20130243773 |
RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES
Provided is methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy... |
|
|
US20120195898 |
Immunizing Compositions and Methods of Use
The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater... |
|
|
US20120301481 |
TARGETING POLY-GAMMA-GLUTAMIC ACID TO TREAT STAPHYLOCOCCUS EPIDERMIDIS AND RELATED INFECTIONS
Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic... |
|
|
US20110217312 |
TARGETING POLY-GAMMA-GLUTAMIC ACID TO TREAT STAPHYLOCOCCUS EPIDERMIDIS AND RELATED INFECTIONS
Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic... |
|
|
US20140120093 |
Anti-Infective Binding Proteins that Bind AIP2
There is disclosed compositions and methods relating to or derived from anti-AIP2 antibodies. More specifically, there is disclosed fully human antibodies that bind AIP2, AIP2-binding fragments... |
|
|
US20150182605 |
Ultra-Low Dose Lysostaphin for Treating MRSA
The present invention is directed to compositions and methods for treating diseases and disorders of patients and, in particular, compositions and methods for treating Staphylococcus infections of... |
|
|
US20120171223 |
HIGH AFFINITY ANTIBODIES THAT NEUTRALIZE STAPHYLOCOCCUS ENTEROTOXIN B
This invention provides antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies... |
|
|
US20150086601 |
METHODS FOR PREVENTING BIOFILM FORMATION
Provided are methods for the treatment or prevention of microbial infections (e.g., nocosomial infection) in which the underlying pathology involves a PNAG-containing microbial bio film. The... |
|
|
US20110038879 |
IMMUNOGENIC AND THERAPEUTIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES
Compositions for preventing and/or treating S. pyogenes infection which comprise one or more active agents. The active agents are SLO antigens, nucleic acid molecules encoding the SLO antigens,... |
|
|
US20130095115 |
STAPHYLOCOCCUS AUREUS LEUKOCIDINS, THERAPEUTIC COMPOSITIONS, AND USES THEREOF
Disclosed herein are isolated and purified Staphylococcus aureus bi-component leukocidin, referred to herein as LukAB, and its components LukA and LukB, antibodies specific to LukA, antibodies... |
|
|
US20120082677 |
COMPOSITIONS FOR THE TREATMENT OF HCV AND HBV
Therapeutic compositions for the treatment of viral hepatitis B (HBV) and hepatitis C (HCV) comprise antistreptokinase and antistreptolysine antibodies and/or tranexamic acid. Three antibodies... |
|
|
US20100092487 |
TOXIC DETECTION METHOD
According to the present invention, an antibody against a Panton-Valentine leukocidin toxin contained in Staphylococcus aureus, a method and a kit for detecting the toxin with the use of the... |
|
|
US20090274704 |
Anti-staphylococcus aureus antibodies
A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody is enriched for immunoglobulins having both an antigen-binding portion that binds... |
|
|
US20060062794 |
Composition containing particle surface charge control agent, particle separating method using same, particle separator
The present invention is a composition for modifying an amount of charges on a surface of a target particle in a sample and separating or quantitatively determining the target particle in the... |
|
|
US20130164308 |
STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODIES AND USES THEREOF
The present invention provides antagonizing antibodies that bind to S. aureus alpha-toxin. The invention further provides a method of obtaining such antibodies and antibody encoding nucleic acids.... |